HC Wainwright Reaffirms Buy Rating for Pliant Therapeutics (NASDAQ:PLRX)
HC Wainwright reaffirmed their buy rating on shares of Pliant Therapeutics (NASDAQ:PLRX – Free Report) in a research report released on Friday, Benzinga reports. HC Wainwright currently has a $38.00 price objective on the stock. Other equities analysts also recently issued reports about the stock. Oppenheimer reduced their price objective on shares of Pliant Therapeutics […]
More Stories
Reviewing Sharing Economy International (OTCMKTS:SEII) & SmartRent (NYSE:SMRT)
SmartRent (NYSE:SMRT – Get Free Report) and Sharing Economy International (OTCMKTS:SEII – Get Free Report) are both small-cap business services...
Digital Ally (NASDAQ:DGLY) Earns Sell Rating from Analysts at StockNews.com
StockNews.com initiated coverage on shares of Digital Ally (NASDAQ:DGLY – Free Report) in a research report sent to investors on...
Acumen Pharmaceuticals (NASDAQ:ABOS) Releases Quarterly Earnings Results, Misses Estimates By $0.14 EPS
Acumen Pharmaceuticals (NASDAQ:ABOS – Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.50) earnings per...
LCI Industries (NYSE:LCII) to Issue Dividend Increase – $1.15 Per Share
LCI Industries (NYSE:LCII – Get Free Report) declared a quarterly dividend on Thursday, November 14th,RTT News reports. Shareholders of record...
CleanSpark (NASDAQ:CLSK) vs. Binah Capital Group (NASDAQ:BCG) Head-To-Head Comparison
CleanSpark (NASDAQ:CLSK – Get Free Report) and Binah Capital Group (NASDAQ:BCG – Get Free Report) are both finance companies, but...
ADVFN (LON:AFN) Shares Down 8.1% – What’s Next?
ADVFN Plc (LON:AFN – Get Free Report)’s share price dropped 8.1% during mid-day trading on Thursday . The company traded...